Cauldron Ferm raises $13.25M to revolutionize precision-fermented protein production
Australian biomanufacturing firm Cauldron Ferm has secured $13.25 million in fresh funding. The investment will help expand its cutting-edge 'hyper-fermentation' technology and meet rising demand from both government and corporate clients. The company is already recognised as a leader in precision-fermented protein production across Australia and the Asia-Pacific region. The latest funding round was led by Main Sequence Ventures, with contributions from Horizons Ventures, SOSV, and NGS Super. Cauldron Ferm stands out as the only Australian business approved to produce precision-fermented protein ingredients at a 10,000-litre scale. Its technology, featuring a unique bioreactor design and custom growth medium, enables continuous fermentation—reducing costs by up to 50% while boosting output by 20% and cutting capital expenditure by 45% compared to traditional methods.
The company currently operates a 30,000-litre demo facility in New South Wales, partly funded by the federal government. Plans are now underway to build a commercial-scale plant in Mackay, Queensland, with a 500,000-litre capacity. Beyond Australia, Cauldron Ferm aims to establish a global network of facilities, including six new sites in Europe, North America, and Asia, with announcements expected in early 2026. Earlier this year, the firm was named one of Fast Company's Most Innovative Asia-Pacific Companies of 2026. Its goal is to become the region's largest end-to-end contract manufacturer for precision-fermented bioproducts, catering to industries from food to pharmaceuticals.
The new funding will accelerate Cauldron Ferm's expansion of its hyper-fermentation platform. With lower production costs and higher efficiency, the company is positioning itself as a key player in industrial-scale biomanufacturing. The upcoming Mackay plant and global sites will further solidify its role in meeting international demand for sustainable bioproducts.
